Project Name: SHSCT Breast Cancer Service Improvement Project
Project Summary:
The project is designed to maximise efficiency and optimise workforce capacity within the SHSCT breast cancer oncology service. This will be achieved by creating three new dedicated workforce roles for a period of two years:
- Band 7 Oncology Breast Clinical Nurse Specialist (CNS)
- Band 6 Breast Cancer Oncology Nurse Specialist
- Band 4 Oncology Support Worker
Objectives:
- Build strong clinical relationships and ensure robust handover from the Surgical Breast Care Nursing Team to the Breast Oncology CNS team.
- Maximise efficiency of clinical appointments, improving the patient pathway from diagnosis to treatment.
- Support the breast oncology multidisciplinary team and coordinate care for patients with both primary and secondary breast cancer.
Role Highlights:
- The Band 7 CNS will lead nurse-led consultations, assess patients independently, initiate investigations, and contribute to multidisciplinary team (MDT) meetings.
- The Band 6 Nurse Specialist will act as a key worker across the care pathway, provide holistic support, and participate in MDT meetings.
- The Band 4 Support Worker will offer holistic care, facilitate personalised care plans, and help patients navigate health and social care systems.
Expected Benefits:
ANTICIPATED BENEFITS FOR PATIENTS
- Increased access to equitable, consistent, and standardised care
- Enhanced experience for patients and their carers who live with a breast cancer diagnosis;
- Increased opportunity to have a personalised care and support plan helping patients to address their concerns
ANTICIPATED BENEFITS FOR THE ORGANISATION
- Increased understanding of the individual patients' needs by the NHS team
- Free up consultant capacity for clinical activities that are unique to their skillset
- Capacity for consultant to see more complex patients
- Enhanced organisational reputation
ANTICIPATED BENEFITS FOR NOVARTIS
Better understanding of overall customers’ and patients’ needs
- Optimal use of medicines (including Novartis medicines) in line with local/national guidance in appropriate patients.
- Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisations
Start Date & Expected Duration: November 2025 for 30 months
FA-11573068 | December 2025